Group 1 - The company, 泰凌医药 (01011), announced that its shares will be temporarily suspended from trading starting at 9:03 AM on February 10, 2026 [1]

Core Viewpoint - Eli Lilly announced the acquisition of Orna Therapeutics for up to $2.4 billion, marking a significant move into the in vivo CAR-T therapy space [3][8]. Group 1: Acquisition Details - The acquisition price of $2.4 billion includes both upfront payments and milestone payments related to clinical development [3]. - Orna Therapeutics is recognized as the first company globally to develop new therapies using engineered circRNA [5]. Group 2: Orna Therapeutics' Innovations - Orna is advancing a new therapy that combines engineered circRNA with novel lipid nanoparticles (LNP) to generate CAR-T cells in vivo, targeting diseases such as B-cell driven autoimmune disorders [6]. - The lead project, ORN-252, is a clinical trial-ready in vivo CAR-T therapy targeting CD19 [6]. Group 3: Industry Context - Eli Lilly's acquisition aligns with recent trends in the industry, where companies like Gilead Sciences and AbbVie have also made significant investments in in vivo CAR-T technologies [8]. - The acquisition is part of Eli Lilly's broader strategy to leverage cash flow from GLP-1 weight loss drugs for further investments in innovative therapies [11].

Core Viewpoint - The continuation of centralized drug procurement in China aims to stabilize clinical medication supply and market expectations for pharmaceutical companies, with over 300 drugs involved in the latest round of procurement [1]. Group 1: Centralized Drug Procurement - The recent centralized procurement process is a key step in ensuring stable clinical medication supply, following the expiration of previous procurement agreements [1]. - The new nationwide unified procurement allows companies to submit a single bid to cover the entire national market, enhancing efficiency compared to previous provincial or inter-provincial procurement methods [1]. - The unified approach is expected to facilitate the establishment of a large national market by consolidating supply and pricing [1]. Group 2: Procurement Details - A total of 316 drugs are included in this round of procurement, with a procurement cycle lasting three years, which is anticipated to further secure clinical medication availability [1]. - The procurement strategy considers multiple factors such as reasonable pricing, reliable quality, stable supply, and sustainable industry development, while also addressing patient medication needs [2].

Core Insights - The small nucleic acid sector is experiencing a significant commercialization phase, driven by technological breakthroughs and successful clinical data releases in the weight loss domain [1][3][6] - Major transactions, including a billion-level acquisition by China Biologic and the Hong Kong listing of Rebio, indicate that capital exit channels are now open [1][5][6] Group 1: Clinical Data Releases - Arrowhead Pharmaceuticals announced clinical data for two siRNA obesity candidates, ARO-INHBE and ARO-ALK7, showing improvements in visceral fat and total fat in obese patients with type 2 diabetes, leading to a 10.9% stock price increase [3] - Wave Life Sciences reported that its siRNA drug WVE-007 achieved a 4.0% weight reduction and a 0.9% muscle gain in a Phase I trial, resulting in a 147.3% stock price surge [4] - The clinical data from these small nucleic acid drugs suggest potential for use either alone or in combination with GLP-1 drugs to reduce fat while preserving muscle [4][7] Group 2: Business Development Transactions - In early 2026, Anlong Bio secured an international strategic cooperation agreement in the small nucleic acid drug field worth over $100 million, marking a significant breakthrough in international business development [5] - China Biologic announced a 1.2 billion RMB acquisition of Hejiya Bio, enhancing its small nucleic acid portfolio and leveraging Hejiya's unique long-acting delivery platform [5][6] - Saintin Bio has engaged in multiple business development deals, including a strategic collaboration with Genentech worth up to $15 billion for RNAi drug development [17] Group 3: Market Trends and Future Outlook - The small nucleic acid sector is increasingly recognized as a core area for innovative drug development, with expectations for more significant events in the future [2][6] - The weight loss market is identified as a potential area for major transactions, driven by the large market size and the growing recognition of clinical efficacy for small nucleic acid drugs [7][19] - Major pharmaceutical companies are actively exploring collaborations in the small nucleic acid space, particularly in conjunction with GLP-1 drugs to enhance therapeutic outcomes [18][20]

在深化社会治安综合治理方面，广东常态化扫黑除恶总体成效稳居全国第一方阵，现发命案实现100% 全破，侦破命案积案和毒品犯罪、电诈案件资金挽损及打击战果均居全国第一，对缅北"四大家族"之首 白家犯罪集团4名首要分子依法执行死刑。2025年全省刑事治安警情、刑事立案同比分别下降17.7%、 10.2%，创本世纪以来最低。在治安重点部位、复杂场所划设"1、3、5分钟"快反圈1535个，重点场所安 防设施应配尽配，交通事故死亡人数持续下降，2024年创近十年最大降幅，2025年再下降11.2%。常态 化推进未成年人违法犯罪预防治理，开展学生欺凌专项排查治理，率先实现所有地市专门矫治教育场所 全覆盖。 司法透明度指数居全国前列 在坚持严格执法公正司法方面，广东全面准确执行宽严相济刑事政策，落实和完善司法责任制，执法司 法质效和公信力全面提升。 全省法院2025年审结各类案件382.75万件，比2022年增长38.08%，平均结案时间缩短一个月，92%的矛 盾纠纷在一审程序中化解，司法透明度指数居全国前列。检察机关5年来批准逮捕各类犯罪嫌疑人38万 余人，依托办案制发社会治理类检察建议6112件，治罪与治理并重的法律监督 ...

（来源：中国医药报） 转自：中国医药报 生产管理的目的是采取有效措施，最大限度地降低药品生产过程中混淆、差错、污染和交叉污染等风 险。药品商业生产阶段质量管理的目的是对药品的工艺性能和产品质量进行监测，确保生产工艺处于一 个稳定、可控的状态并持续进行改进。 追溯管理 新修订《中华人民共和国药品管理法》对药品研制、生产、经营、使用活动中信息的真实、准确、完整 和可追溯提出了明确要求。 追溯性是医药企业质量管理方式的一种体现形式。从物料进厂至产品出厂的每个环节，物料、中间产 品、成品均有唯一的身份标识，以实现产品生命周期内的有效追溯。产品生产过程中追溯性的建立，通 常采用的方式是批号管理。结合制药行业信息化的实施，信息化系统的应用同样也是依赖于生产不同阶 段输入物及产出物的唯一身份（条码或批号）标识进行识别及管理。批号的"唯一性"至关重要。标识是 企业建立药品生产过程中追溯性的一种有效方式。生产过程中设备、物料的正确标识也是一种有效降低 生产过程中出现差错和混淆的控制手段。 制等相关的产品进行注册批准后的变更，企业均应根据相关产品批准后变更指导原则实施。 此外，文件和记录的可追溯性也很重要。药品生产过程中各类操作 ...

（来源：中国医药报） 自2019年新修订《中华人民共和国药品管理法》正式确立药品上市许可持有人（以下简称持有人或 MAH）制度以来，药品委托生产已从特殊时期的"补充措施"转变为优化资源配置、促进产业分工的"常 态模式"。这一转变极大地激发了市场活力，但也对药品全生命周期质量安全监管提出了全新挑战。如 何确保"持证方"与"生产方"责任无缝衔接，共同筑牢药品质量防线，成为做好药品监管工作的重要命 题。为此，国家药监局近年来连续出台重磅文件，构建起一个层层递进、日趋严密的药品委托生产监管 体系。 从2022年底聚焦持有人的《药品上市许可持有人落实药品质量安全主体责任监督管理规定》（以下简称 《规定》），到2023年细化持有人委托生产管理的《关于加强药品上市许可持有人委托生产监督管理工 作的公告》（以下简称132号公告），再到2026年初最新出台、直指受托生产企业的《关于加强药品受 托生产监督管理工作的公告》（以下简称《公告》），一条清晰的政策演进路径跃然纸上，标志着我国 药品委托生产监管正从"强调一方主体责任"迈向"压实双方共同责任"的新阶段。 转自：中国医药报 政策演进—— 这一监管体系的构建，并非一蹴而就，而是 ...

（来源：中国医药报） 通过多层次、系统化的严监管举措，海南省药品安全基本面持续稳固。去年，未发生区域性、系统性药 品安全风险，企业质量管理体系不断优化；已有10家医药企业通过国际相关认证，产业竞争力稳步提 升。 优化检查流程 减轻企业负担 "监管既要守牢安全底线，也要为产业发展留足空间"，这是海南自贸港医药产业快速发展对药品监管提 出的现实要求。去年8月，《海南省药品监督管理局关于优化药品注册生产现场检查若干措施的通告》 （以下简称《通告》）发布实施，优化多项检查流程，涵盖部分行政许可检查、再注册恢复生产检查、 药品GMP（生产质量管理规范）符合性检查及变更制剂生产场地检查等。 转自：中国医药报 □ 卢进梅 近年来，海南省药品查验中心立足全省医药产业快速发展和海南自贸港封关运作的新形势，聚焦监管效 能与产业服务双提升，通过分级监管、优化流程、强化服务等举措，努力打造自贸港药品检查新范式， 为药品安全与产业高质量发展注入新动能。 创新监管机制 防控药品风险 面对有限的监管资源与日益复杂的监管形势，海南省药品查验中心主动求变，聚焦医药产业薄弱环节， 持续拓展检查广度、深挖检查深度、加大检查力度，织密药品安全风险防 ...

Core Viewpoint - The company, 英硅智能, has announced a strategic collaboration with 康哲药业 for drug development, focusing on AI-powered innovative drug research in the central nervous system and autoimmune diseases [1] Group 1: Collaboration Details - The partnership will leverage 英硅智能's validated AI platform and innovative drug development capabilities alongside 康哲药业's experienced research team and deep understanding of disease areas [1] - The agreement stipulates the joint development of at least two research projects [1] Group 2: Financial Aspects - 英硅智能 is expected to receive up to several tens of millions of Hong Kong dollars in research funding for each project [1]

Core Viewpoint - Insilico Medicine (03696) has announced a strategic collaboration with Kanghong Pharmaceutical for drug development, focusing on AI-enabled innovative drug research in central nervous system and autoimmune disease areas [1] Group 1: Collaboration Details - The collaboration will leverage Insilico's validated AI platform and innovative drug development capabilities alongside Kanghong's experienced research team and deep understanding of disease areas [1] - The agreement stipulates that both parties will jointly advance at least two research projects [1] Group 2: Financial Aspects - Insilico is expected to receive research funding support of up to several tens of millions of Hong Kong dollars for each project [1]